Overview

An Exploratory Clinical Study Evaluating the Efficacy and Safety of Tunlametinib Combined With Fruquintinib in the Third-line Treatment of Advanced Colorectal Cancer Patients With RAS Mutations.

Status:
NOT_YET_RECRUITING
Trial end date:
2028-04-27
Target enrollment:
Participant gender:
Summary
This study is a prospective, open-label, single-arm clinical study aimed at evaluating the efficacy and safety of Tunlametinib combined with Fruquintinib in the third-line treatment of advanced colorectal cancer patients with RAS mutations.
Phase:
NA
Details
Lead Sponsor:
Liu Huang
Treatments:
HMPL-013